From Annual Report - Geoff Pocock ... Other current...

From Annual Report - Geoff Pocock ... Other current directorships: EMVision Medical Devices Ltd (ASX:EMV)

Quite an interesting story going on here ... EMV ... huge synergy.

EMVision Medical Devices Limited is an Australia-based medical device company developing an approach to looking inside the human body. The Company is engaged in the research and development of medical imaging and diagnostic technology (the EMVision Technology), for the purpose of commercializing a portable medical device for stroke diagnosis and monitoring as well as other medical imaging needs. The Company is developing and commercializing medical imaging diagnostics for various disease states and medical emergencies. The Company’s product pipeline includes portable, non-invasive, neuroimaging devices. Its lead product in development includes a portable, non-ionizing brain scanner, capable of producing images of biological tissue to provide insights for clinicians. Its second-generation device is an ultra-light weight device embedded in standard road and air ambulances to deliver pre-hospital stroke diagnosis and care to patients regardless of location.

There are many similarities in the charts for both (AGN, EMV) although EMV is a little advanced and consolidating more whereas AGN has a weird semi-triangular (probably continuation?) pattern formed here.

It's probably worth noting that if I compare three or five year charts of a few unloved biotechs, both AGN and EMV have broken out of their down trend while many others have yet to.

At a most significant point in time for AGN now. The (charts) triangle is getting to the pointy end and volume is drying up ... perhaps a fortnight for a breakout (or so). Fancy that!

• Dosing of first patients in the Phase 2 trial is on track to commence in March 2024.